Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma

Rapezzi, Davide; Sticchi, Laura; Racchi, Omar; Mangerini, Rosa; Ferraris, Anna Maria; Gaetani, Gian Franco

doi:10.1034/j.1600-0609.2003.00028.x

Cited by 55 publications

(31 citation statements)

References 22 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Whereas influenza vaccination of healthy individuals can induce humoral immune responses in 60-90%, 4 most studies in immunocompromised patients show lower rates of efficacy varying between 10 and 50% using serological end points for controlling responses to vaccination. [5][6][7][8][9][10] Although antibodies play critical roles in protection, activation of T-lymphocytes, in particular, the CD4 þ helper subpopulation is essential for supporting virusspecific effector cell functions. 11 Few studies have addressed the possibility to investigate cell-mediated immune response as a marker of vaccine responsiveness.…”

Section: -4mentioning

confidence: 99%

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

Avetisyan

Ragnavölgyi

Tóth

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

Summary:Influenza is one of the most common respiratory diseases in humans. The response to vaccination is frequently poor in immunosuppressed individuals. The aim of the present study was to develop an enzyme-linked immunospot (ELISPOT) assay for measuring of the specific T-cell response to influenza vaccination. In all, 18 healthy subjects and six stem cell transplantation (SCT) patients tested before and 4 weeks after influenza vaccination were included in the present study. Peripheral blood lymphocytes were stimulated with four influenza peptides; three based on sequences from the hemagglutinin and one from the M1 protein. The ELISPOT assay and the measurement of intracellular IFN-c production were used to determine the cell-mediated responses after stimulation with the peptides. Influenza vaccination elicited strong cell-mediated immune responses in the healthy controls to all four peptides with 3.2-6.9-fold increases in the number of IFN-c producing spots/10 6 cells. By intracellular staining, it was suggested that CD4 þ cells mediated the responses to the hemagglutinin peptides. In contrast, there was no increase in the number of IFN-c producing cells response after vaccination in the six SCT patients. In conclusion, our results suggest that the ELISPOT assay might be used as a complement to serology for monitoring of future influenza vaccine studies in SCT patients. Bone Marrow Transplantation (2005) 36, 411-415.

show abstract

Section: -4mentioning

confidence: 99%

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

Avetisyan

Ragnavölgyi

Tóth

et al. 2005

Bone Marrow Transplant

View full text Add to dashboard Cite

show abstract

“…Patients who are young, have early-stage disease, have not received chemotherapy, and do not have hypogammaglobulinemia have the greatest chance to benefit from vaccination [73][74][75]. Vaccine strategies have been tried for influenza, pneumococcus, hemophilus, and tetanus [74,76,77]. Elevated levels of serum histamine have been reported, possibly associated with immunodeficiency in patients with CLL.…”

Section: Vaccination Strategiesmentioning

confidence: 97%

Immunologic monitoring in chronic lymphocytic leukemia

Wierda

2003

Curr Oncol Rep

View full text Add to dashboard Cite

Chronic lymphocytic leukemia (CLL) is characterized by progressive defects in humoral- and cell-mediated immunity. These defects are manifested as a propensity to develop infections with encapsulated bacteria, and less frequently, with gram-negative enterics. In addition, reactivation of viruses such as herpesvirus is not uncommon. Treatment of the disease further exacerbates immunosuppression by depleting immune effectors and broadening the spectrum of potentially offending pathogens. Risk of infection can potentially be reduced by administration of intravenous immunoglobulin and use of prophylactic antibiotics for individuals who are at high risk. Current work focuses on development of cellular and cytokine therapy to facilitate immune reconstitution in patients with CLL, thereby reducing morbidity and mortality and potentially improving survival.

show abstract

“…30 The B-lymphocyte dysfunction favours encapsulated bacteria infections, especially Streptococcus pneumoniae or Haemophilus influenza. 31,32 Staphylococcus aureus and Gramnegative bacilli are more frequent in patients with advanced disease and kidney failure.…”

Section: Symptomsmentioning

confidence: 99%

Management of multiple myeloma in older people

Bolaños

Iñigo

Benavente

et al. 2014

Rev. Clin. Gerontol.

View full text Add to dashboard Cite

Multiple myeloma is a neoplastic proliferation of a plasma cell clone that produces a monoclonal immunoglobulin. It is one of the most common haematological malignancies and the incidence increases with age, with a median age at diagnosis of 65-70 years. The diagnosis of multiple myeloma requires the presence of ࣙ10% plasma cells in the bone marrow and an M-protein in serum and/or urine. Cytogenetic status, serum β 2 -microglobulin and response to therapy are the key prognostic factors. Treatment is necessary for the patient diagnosed with symptomatic multiple myeloma, with organ damage. Patients older than 65 years are ineligible for autologous transplantation. The introduction of novel agents, such as thalidomide, bortezomib and lenalidomide, have changed the management of myeloma and extended overall survival. However, in older patients the results are not as satisfactory and treatment strategies have to be individualized to improve tolerability and optimize efficacy.

show abstract

Influenza vaccine in chronic lymphoproliferative disorders and multiple myeloma

Abstract: Influenza vaccine is effective and well tolerated in patients with CLPD and MM. No contraindications exist for its use, and it should become a routine practice, in order to prevent serious complications during the influenza epidemic season.

Cited by 55 publications

References 22 publications

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

Cell-mediated immune responses to influenza vaccination in healthy volunteers and allogeneic stem cell transplant recipients

Immunologic monitoring in chronic lymphocytic leukemia

Management of multiple myeloma in older people

Contact Info

Product

Resources

About